<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">27169526</PMID>
<DateCompleted>
<Year>2018</Year>
<Month>03</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1863-9941</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>43</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2017</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>European journal of trauma and emergency surgery : official publication of the European Trauma Society</Title>
<ISOAbbreviation>Eur J Trauma Emerg Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>sTREM-1, sIL-2Rα, and IL-6, but not sCD163, might predict sepsis in polytrauma patients: a prospective cohort study.</ArticleTitle>
<Pagination>
<MedlinePgn>363-370</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00068-016-0678-1</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To investigate whether sTREM-1, sIL-2Rα, sCD163, and IL-6 predict septic complications following polytrauma. Prospective observational study in a university hospital intensive care unit.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Blood samples were drawn on admission, 24 and 48 h after the injury from 64 adult polytrauma patients. The occurence of infectious complications was investigated. The sepsis-free rates for the multiple trauma patients were considered as end points in the Kaplan-Meier plot analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Upon admission, sIL-2Rα mean values were higher in the T group compared to the T&amp;S patients (1789 ± 1027 pg/mL versus 1280 ± 605 pg/mL, p = 0.02). The initial mean values of sTREM-1, IL-6, and sCD163 did not discriminate between the T and T&amp;S groups patients (p &gt; 0.05). sTREM-1 cutoff was 62 pg/mL: the sepsis-free rates differed significantly between the patients with sTREM-1 concentrations lower and higher than the cutoff (80 versus 48 %, p &lt; 0.01). From the patients with serum sIL-2Rα ≥1593 pg/mL, 86 % did not present sepsis; for sIL-2Rα values in the range 946-1593 pg/mL, the sepsis-free rate was 68 %, while from the patients with sIL-2Rα &lt;945 pg/mL, only 40 % remained sepsis-free (p = 0.05). sCD163 cutoff of 1000 ng/mL did not discriminate between the patients (76 versus 64 %, p = 0.28). For IL-6, the sepsis-free rates differed significantly between the patients with concentrations lower and higher than 400 pg/mL (78 versus 38 %, p &lt; 0.01).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">sTREM-1, sIL-2Rα, and IL-6, but not CD163, may be used as prognostic markers for the occurrence of sepsis in multiple trauma patients.</AbstractText>
<AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Level II-Diagnostic tests and criteria.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Trancă</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Anaesthesia and Intensive Care II, Clinical Emergency County Hospital of Cluj, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, 400006 Clinicilor 3-5, Cluj-Napoca, Romania. sebi_tranca@yahoo.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Oever</LastName>
<ForeName>J T</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ciuce</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Surgical Department I, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Netea</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Slavcovici</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Infectious Diseases, "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Petrișor</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Anaesthesia and Intensive Care II, Clinical Emergency County Hospital of Cluj, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, 400006 Clinicilor 3-5, Cluj-Napoca, Romania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hagău</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Anaesthesia and Intensive Care II, Clinical Emergency County Hospital of Cluj, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, 400006 Clinicilor 3-5, Cluj-Napoca, Romania.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2016</Year>
<Month>05</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Eur J Trauma Emerg Surg</MedlineTA>
<NlmUniqueID>101313350</NlmUniqueID>
<ISSNLinking>1863-9933</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015214">Antigens, Differentiation, Myelomonocytic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C085464">CD163 antigen</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053645">Interleukin-2 Receptor alpha Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000073871">Triggering Receptor Expressed on Myeloid Cells-1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015214">Antigens, Differentiation, Myelomonocytic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003422">Critical Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006785">Hospitals, University</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053645">Interleukin-2 Receptor alpha Subunit</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D009104">Multiple Trauma</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012383">Romania</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018805">Sepsis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000073871">Triggering Receptor Expressed on Myeloid Cells-1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Sepsis</Keyword>
<Keyword MajorTopicYN="N">Trauma</Keyword>
<Keyword MajorTopicYN="N">sCD163</Keyword>
<Keyword MajorTopicYN="N">sIL-2Rα</Keyword>
<Keyword MajorTopicYN="N">sTREM-1</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2016</Year>
<Month>01</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2016</Year>
<Month>05</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2018</Year>
<Month>3</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>5</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27169526</ArticleId>
<ArticleId IdType="doi">10.1007/s00068-016-0678-1</ArticleId>
<ArticleId IdType="pii">10.1007/s00068-016-0678-1</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Shock. 1996 Mar;5(3):157-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8696979</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Infect Dis. 2012 Jul 18;12 :157</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22809118</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care. 2011;15(2):R115</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21496225</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Immunol. 2006 Sep;145(3):448-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16907912</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care. 2005 Oct 5;9(5):485-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16277737</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Scand J Clin Lab Invest. 2012 Feb;72(1):1-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22060747</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Clin Microbiol Infect Dis. 2014 Mar;33(3):313-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23990136</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care Med. 2011 Apr;39(4):621-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21242798</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Surg. 2009 Mar;33(3):558-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19148699</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Immunol. 1991 Sep;85(3):515-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1893634</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2012;7(12):e51862</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23251644</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Shock. 2012 Feb;37(2):145-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22089204</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Allergy Clin Immunol. 2011 Mar;127(3):701-21.e1-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21377040</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2014 Mar 17;9(3):e92331</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24637679</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mediators Inflamm. 2013;2013:819246</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23861562</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Med Res. 2004 Aug;2(3):181-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15931355</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Technol Health Care. 2010;18(2):89-100</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20495248</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Acta Medica (Hradec Kralove). 2009;52(2):57-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27849148</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Injury. 2005 Jun;36(6):691-709</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15910820</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Immunol. 1992 Oct;90(1):36-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1382903</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Injury. 2013 Dec;44(12 ):1680-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24119650</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Biochem. 2010 Jun;43(9):720-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20303344</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mediators Inflamm. 1993;2(1):3-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18475497</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem J. 1994 Jun 1;300 ( Pt 2):281-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8002928</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2014 Oct 18;384(9952):1455-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25390327</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care. 2012 Nov 29;16(6):R229</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23194114</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Infect Dis. 2011 Nov 04;11:309</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22050935</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2010 Mar 4;464(7285):104-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20203610</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 2004 Dec 6;200(11):1419-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15557347</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunobiology. 2005;210(2-4):153-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16164022</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care Med. 2013 Feb;41(2):580-637</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23353941</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care. 2010;14(1):R15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20144219</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2012;7(7):e38400</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22911680</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Acta Medica (Hradec Kralove). 2009;52(2):57-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19777868</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>